Cambrex Co. (CBM) Expected to Announce Quarterly Sales of $184.15 Million

Analysts forecast that Cambrex Co. (NYSE:CBM) will announce sales of $184.15 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Cambrex’s earnings, with the highest sales estimate coming in at $185.04 million and the lowest estimate coming in at $183.27 million. Cambrex posted sales of $177.87 million during the same quarter last year, which would indicate a positive year over year growth rate of 3.5%. The business is expected to announce its next quarterly earnings results on Thursday, February 8th.

On average, analysts expect that Cambrex will report full-year sales of $184.15 million for the current financial year, with estimates ranging from $529.85 million to $537.22 million. For the next year, analysts anticipate that the firm will report sales of $542.03 million per share, with estimates ranging from $540.16 million to $543.90 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Cambrex.

Cambrex (NYSE:CBM) last announced its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.17. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The company had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. During the same period in the previous year, the company posted $1.23 earnings per share. Cambrex’s revenue for the quarter was up 2.5% on a year-over-year basis.

A number of research analysts have issued reports on CBM shares. Craig Hallum reissued a “buy” rating and issued a $60.00 price target (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Finally, William Blair initiated coverage on Cambrex in a report on Tuesday, January 16th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $60.00.

Cambrex (NYSE CBM) opened at $51.10 on Friday. Cambrex has a twelve month low of $42.55 and a twelve month high of $62.95. The stock has a market capitalization of $1,730.00, a P/E ratio of 16.75, a price-to-earnings-growth ratio of 1.24 and a beta of 2.38.

Hedge funds have recently made changes to their positions in the company. Advisor Group Inc. raised its stake in shares of Cambrex by 29.8% during the 2nd quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after buying an additional 615 shares during the period. Visionary Asset Management Inc. acquired a new position in shares of Cambrex during the 3rd quarter worth approximately $201,000. Trexquant Investment LP acquired a new position in shares of Cambrex during the 3rd quarter worth approximately $209,000. Flinton Capital Management LLC raised its stake in shares of Cambrex by 90.9% during the 2nd quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock worth $213,000 after buying an additional 1,700 shares during the period. Finally, Sei Investments Co. raised its stake in shares of Cambrex by 3,120.9% during the 3rd quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock worth $228,000 after buying an additional 4,026 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Cambrex Co. (CBM) Expected to Announce Quarterly Sales of $184.15 Million” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.com-unik.info/2018/02/09/cambrex-co-cbm-expected-to-announce-quarterly-sales-of-184-15-million.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit